Ask VialBase
immune

Vilon

Also known as: Lys-Glu, KE peptide, Vilon dipeptide
Preliminary evidence FDA: Not FDA-approved WADA: Not listed

Vilon is a synthetic dipeptide (Lys-Glu, "KE") from the Khavinson family of short-peptide bioregulators, studied as a thymic/immune "Cytogen." Research — largely in vitro and Russian-language — suggests it acts as an epigenetic regulator, shifting expression of ageing- and immune-related genes to restore thymic activity in aged tissue. It is not FDA-approved and lacks Western clinical trials. For educational purposes only. Not medical advice. Vilon is the dipeptide Lys-Glu (KE) — one of the shortest peptides reported to be biologically active. Its proposed mechanism is epigenetic, not receptor-mediated: 1. Gene-expression modulation. Short peptides of this class are thought to penetrate

This content is for educational and research purposes only. VialBase does not provide medical advice. Consult a healthcare professional before using any peptide.

Molecular weight 275.3 Da
Half-life ~minutes estimated;
CAS number 45234-02-4
Route Subcutaneous · Oral · Sublingual subcutaneous preferred
02

Mechanism

Short thymic dipeptide (Lys-Glu) proposed to act as an epigenetic regulator — binding gene-promoter regions and modulating expression of genes tied to immune function and cellular senescence. In vitro it alters expression of SIRT1, PARP1/PARP2 and other ageing-associated genes, and has been studied for restoring thymic/T-cell activity in aged tissue. Effects are reported mainly in Russian gerontology research and cell-culture models, not FDA-grade human trials.

03

Dosing

DOSE RANGE 10–20 mg per cycle
FREQUENCY 1×/day
CYCLE LENGTH 10–20 days, repeated 2–4×/year

Short pulsed cycles rather than continuous use, following the Khavinson bioregulator pattern. Oral/sublingual and subcutaneous routes are both described in practitioner protocols; bioavailability data is not published.

04

Research summary

Study Type Year Key Finding
Effects of short peptides on thymocyte blast transformation and signal transduction In vitro (thymocytes) 2002 Short thymic peptides influenced thymocyte blast transformation and intracellular signal transduction
Comparison of the Effects of KE and AED Peptides on Functional Activity of Human Skin Fibroblasts In vitro (human fibroblasts) 2020 The KE dipeptide (Vilon) influenced the functional activity of human skin fibroblasts during in-vitro ageing
KE peptide regulates SIRT1, PARP1 and PARP2 gene expression and protein synthesis in human mesenchymal stem cells In vitro (human MSC) 2023 The KE dipeptide (Vilon) modulated expression of SIRT1, PARP1 and PARP2 — genes central to sirtuin signalling and DNA repair
05

Stacking & interactions

Layered thymic / immune support (peptide + polypeptide complex)

Immune modulation stack

Longevity protocol — immune + pineal/telomere axes

06

Sourcing

Current prices

Updated today

20mg

Stocks this compound Third-party tested Public COAs Positive rep

Save 15% with code VIALBASE at checkout

Stocks this compound Third-party tested Public COAs Positive rep
Stocks this compound Third-party tested Public COAs

VialBase may earn a commission on purchases through partner links — never at additional cost to you. Full disclosure.

Also vetted at
What bloodwork do I need?

Reference ranges are general guidelines. Consult your physician for interpretation.

PRE-CYCLE
  • CMP
  • CBC with differential
DURING CYCLE
  • CBC with differential
POST-CYCLE
  • CMP
  • CBC
Safety & Regulatory Status
FDA STATUS Not FDA-approved
WADA STATUS Not listed

Regulatory status for Vilon may change. Verify current status with your jurisdiction before use. This is not legal or medical advice.

Frequently Asked Questions

What is Vilon?
Vilon is a synthetic dipeptide (Lys-Glu, also written "KE") from the Khavinson family of short-peptide bioregulators developed at the St. Petersburg Institute of Bioregulation and Gerontology. It is classed as a thymic/immune "Cytogen" and is studied as a geroprotector that modulates immune-related gene expression.
What does the research on Vilon actually show?
The strongest data are in vitro. The KE dipeptide has been shown to change expression of ageing-associated genes including SIRT1 and PARP1/PARP2 in human cells, and short thymic peptides of this class influence thymocyte activity and immune signalling. Human evidence is limited to Russian-language clinical reports; there are no FDA-registered trials, so the evidence tier is preliminary.
What is Vilon's peptide sequence?
Vilon is the dipeptide L-lysyl-L-glutamic acid (Lys-Glu / KE), molecular weight ≈275 Da. It is one of the shortest peptides reported to have biological activity.
How is Vilon dosed?
Practitioner protocols use short pulsed courses of roughly 10–20 mg per cycle for 10–20 days, repeated two to four times a year, by subcutaneous injection or orally/sublingually. These are traditional Khavinson-style regimens, not doses validated in controlled human trials.
Is Vilon FDA-approved?
No. Vilon is not approved by the FDA, is not on the 503A compounding list, and is sold only as a research chemical. It is used within Russian bioregulatory medicine. It is not prohibited by WADA.

References

  1. Khavinson VKh et al.. Effects of short peptides on thymocyte blast transformation and signal transduction. Bull Exp Biol Med (2002). PMID: 12420072
  2. Fridman NV et al.. Comparison of the Effects of KE and AED Peptides on Functional Activity of Human Skin Fibroblasts. Bull Exp Biol Med (2020). PMID: 33231794
  3. Khavinson VK et al.. KE peptide regulates SIRT1, PARP1 and PARP2 gene expression and protein synthesis in human mesenchymal stem cells. Adv Gerontol (2023). PMID: 37782636